Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
Innovent Biologics Inc (OTC:IVBXF) and Sanofi SA (NASDAQ:SNY) have collaborated to develop and commercialize two Sanofi clinical-stage oncology assets – Phase 3 SAR408701…
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
FDA AdComm Votes Against Lilly’s Lung Cancer Drug, Sintilimab
The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.
Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate
Privately-held UNION therapeutics A/S and Innovent Biologics Inc’s (OTC:IVBIY) subsidiary have entered into a strategic collaboration and license agreement to develop and commercialize orismilast…
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
Innovent Biologics Inc (OTC:IVBIY) and Bolt Biotherapeutics Inc (NASDAQ:BOLT) have entered into a drug research and development collaboration…
Innovent’s Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
Innovent Biologics Inc (OTC:IVBIY) has announced topline results from Phase 3 ORIENT-16 study evaluating sintilimab, meeting the primary endpoint of overall…
Innovent – Eli Lilly’s Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients
Innovent Biologics Inc (OTC:IVBIY) and Eli Lilly And Co (NYSE:LLY) have announced new and updated data from the ORIENT-11 Phase 3 study of…
Innovent Biologics – Incyte’s Pemigatinib Application Under Review In China For Bile Duct Cancer
The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc’s (OTC:IVBIY) marketing application seeking approval for…
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC:IVBXF) and Eli Lilly And Co’s (NYSE:LLY) Tyvyt (sintilimab injection)…